Tin tức & Cập nhật
Lọc theo Chuyên ngành:

Which factors predict mortality in advanced HCC?
A study has found the high bilirubin, pretreatment hypoalbuminemia, and biochemical tests indicative of hepatic or renal dysfunctions are independently associated with short-term mortality in patients with advanced hepatocellular cancer (HCC) receiving atezolizumab and bevacizumab (Atezo/Bev).
Which factors predict mortality in advanced HCC?
01 Mar 2024
Dietary niacin may protect against death in NAFLD
Dietary niacin intake may benefit individuals with nonalcoholic fatty liver disease (NAFLD), with a study suggesting that a higher intake lowers the risk of mortality.
Dietary niacin may protect against death in NAFLD
13 Feb 2024
Immunotherapy, TACE-based regimen may reshape HCC treatment landscape
In the EMERALD-1 trial, durvalumab plus bevacizumab (D+B) combined with transarterial chemoembolization (TACE) improved progression-free survival (PFS) in individuals with unresectable hepatocellular carcinoma (HCC) eligible for embolization.
Immunotherapy, TACE-based regimen may reshape HCC treatment landscape
13 Feb 2024
Noncontrast-enhanced MRI superior to US but less cost-effective for HCC screening
Noncontrast-enhanced magnetic resonance imaging (NCEMRI) demonstrates superiority over ultrasonography (US) for the surveillance of hepatocellular carcinoma (HCC) in at-risk populations, although this strategy is more expensive than US, according to a Singapore study.
Noncontrast-enhanced MRI superior to US but less cost-effective for HCC screening
31 Jan 2024
Vaccines protect liver disease patients against severe COVID-19
Patients with liver disease develop antibodies and T-cell responses following three shots of COVID-19 vaccines, while those who have been infected with SARS-CoV-2 develop mild symptoms only, reports a recent study.